The 30 immune checkpoints, including PD-1, PD-L1, and CTLA-4 was significantly upregulated in the low-risk group, suggesting that immune checkpoint inhibitors could be more effective in BC patients with the low-risk signature score. Here, PDCD1 is linked to breast cancer.